Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
2(40.0%)
Phase 3
1(20.0%)
N/A
1(20.0%)
Early Phase 1
1(20.0%)
5Total
Phase 1(2)
Phase 3(1)
N/A(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07241169Early Phase 1Recruiting

The Safety and Efficacy of ZVS106e in the Treatment of IRDs Caused by Biallelic Mutations in ABCA4

Role: collaborator

NCT07307469Not ApplicableEnrolling By Invitation

Compassionate Administration of ZVS101e Injection for Extended Treatment

Role: lead

NCT06952842Phase 1Not Yet Recruiting

Safety and Efficacy of ZVS203e in the Treatment of Retinitis Pigmentosa Caused by RHO Gene Mutation

Role: lead

NCT06743646Phase 3Recruiting

Efficacy and Safety of ZVS101e in Patients With Bietti 's Crystalline Dystrophy

Role: lead

NCT05832684Phase 1Active Not Recruiting

Safety and Efficacy of ZVS101e in Patients With Bietti 's Crystalline Dystrophy

Role: lead

All 5 trials loaded